Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBIT Margin (2023 - 2025)

Immunocore Holdings' EBIT Margin history spans 3 years, with the latest figure at 18.85% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 430.0% year-over-year to 18.85%; the TTM value through Dec 2025 reached 11.34%, up 1138.0%, while the annual FY2025 figure was 11.34%, 1138.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 18.85% at Immunocore Holdings, down from 6.92% in the prior quarter.
  • Across five years, EBIT Margin topped out at 3.85% in Q1 2025 and bottomed at 37.57% in Q1 2024.
  • The 3-year median for EBIT Margin is 21.53% (2023), against an average of 19.45%.
  • The largest annual shift saw EBIT Margin tumbled -1069bps in 2024 before it surged 3372bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 24.3% in 2023, then grew by 5bps to 23.14% in 2024, then increased by 19bps to 18.85% in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EBIT Margin are 18.85% (Q4 2025), 6.92% (Q3 2025), and 15.18% (Q2 2025).